Dimensional Fund Advisors LP Sells 588,383 Shares of AbbVie Inc. $ABBV

Dimensional Fund Advisors LP cut its position in AbbVie Inc. (NYSE:ABBV) by 6.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,908,381 shares of the company’s stock after selling 588,383 shares during the quarter. AbbVie comprises about 0.4% of Dimensional Fund Advisors LP’s portfolio, making the stock its 19th biggest holding. Dimensional Fund Advisors LP’s holdings in AbbVie were worth $2,062,253,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Diversified Trust Co grew its position in shares of AbbVie by 23.6% during the 3rd quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock valued at $13,215,000 after acquiring an additional 10,891 shares during the period. Permanent Capital Management LP bought a new stake in AbbVie during the third quarter valued at about $720,000. Railway Pension Investments Ltd increased its position in AbbVie by 33.0% in the third quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock worth $197,723,000 after buying an additional 211,800 shares in the last quarter. World Investment Advisors raised its stake in shares of AbbVie by 9.4% in the third quarter. World Investment Advisors now owns 113,925 shares of the company’s stock worth $26,378,000 after buying an additional 9,811 shares during the period. Finally, Charles Schwab Trust Co lifted its position in shares of AbbVie by 93.4% during the 3rd quarter. Charles Schwab Trust Co now owns 32,105 shares of the company’s stock valued at $7,434,000 after buying an additional 15,502 shares in the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on ABBV shares. Morgan Stanley upped their price target on shares of AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. Royal Bank Of Canada initiated coverage on AbbVie in a report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price target on the stock. UBS Group dropped their price objective on AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a research note on Thursday, February 5th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and set a $223.00 target price on shares of AbbVie in a research report on Wednesday, January 28th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and a consensus target price of $253.15.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive topline Phase 3 AFFIRM results for risankizumab (SKYRIZI) subcutaneous induction in moderately to severely active Crohn’s disease, showing superiority vs. placebo and no new safety signals — a material clinical win that expands AbbVie’s immunology franchise and supports future uptake. AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn’s Disease
• Positive Sentiment: FDA approval for an oral combination of VENCLEXTA and acalabrutinib in previously untreated CLL adds an approved hematology-oncology option to AbbVie’s portfolio, supporting long-term revenue diversification in oncology. AbbVie’s New Data And Approval Test Growth And Valuation Story
• Positive Sentiment: Planned $380M investment to build two new active pharmaceutical ingredient manufacturing facilities in Illinois signals capacity expansion, vertical integration and potential margin/production benefits over time. Is AbbVie Inc. (ABBV) One of the Best Cancer Stocks to Invest In Now?
• Positive Sentiment: Multiple analyst/outlet pieces highlight AbbVie’s attractive dividend yield and steady payout growth, which can support investor demand from income-oriented funds and long-term investors. Why AbbVie Stock May Be the Ultimate Option for Dividend Investors
• Neutral Sentiment: Management will present at the Leerink Partners Global Healthcare Conference (fireside chat on March 10), providing another opportunity for guidance clarity and incremental investor Q&A but not an immediate catalyst. AbbVie to Present at the Leerink Partners Global Healthcare Conference
• Neutral Sentiment: Mentions in industry reports on continuous manufacturing and market trends underscore structural tailwinds for pharma manufacturing efficiency but are longer‑term and indirect for AbbVie’s near-term stock moves. Continuous Manufacturing Market Trends and Global Forecasts, 2035 Featuring Key Players – AbbVie…
• Negative Sentiment: Despite the positive headlines, the stock is down today — likely reflecting short‑term profit-taking and a stretched valuation/PE that makes the name sensitive to market rotation and earnings expectations in the near term.

AbbVie Stock Performance

Shares of ABBV opened at $233.44 on Wednesday. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The company has a 50 day moving average price of $224.56 and a 200-day moving average price of $223.66. The stock has a market capitalization of $412.76 billion, a PE ratio of 98.92, a PEG ratio of 0.81 and a beta of 0.34.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. AbbVie’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same period last year, the business earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.0%. The ex-dividend date is Wednesday, April 15th. AbbVie’s payout ratio is 293.22%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.